Abstract
Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR–ABL genetic translocation and constitutive activation of the Abl tyrosine kinase. Among members of the Signal Transducers and Activators of Transcription (STAT) family of transcription factors, Stat5 is activated by the Bcr–Abl kinase and is implicated in the pathogenesis of CML. We recently identified PD180970 as a new and highly potent inhibitor of Bcr–Abl kinase. In this study, we show that blocking Bcr–Abl kinase activity using PD180970 in the human K562 CML cell line resulted in inhibition of Stat5 DNA-binding activity with an IC50 of 5 nM. Furthermore, abrogation of Abl kinase-mediated Stat5 activation suppressed cell proliferation and induced apoptosis in K562 cells, but not in the Bcr–Abl-negative myeloid cell lines, HEL 92.1.7 and HL-60. Dominant-negative Stat5 protein expressed from a vaccinia virus vector also induced apoptosis of K562 cells, consistent with earlier studies that demonstrated an essential role of Stat5 signaling in growth and survival of CML cells. RNA and protein analyses revealed several candidate target genes of Stat5, including Bcl-x, Mcl-1, c-Myc and cyclin D2, which were down-regulated after treatment with PD180970. In addition, PD180970 inhibited Stat5 DNA-binding activity in cultured primary leukemic cells derived from CML patients. To detect activated Stat5 in CML patient specimens, we developed an immunocytochemical assay that can be used as a molecular end-point assay to monitor inhibition of Bcr–Abl signaling. Moreover, PD180970 blocked Stat5 signaling and induced apoptosis of STI-571 (Gleevec, Imatinib)-resistant Bcr–Abl-positive cells. Together, these results suggest that the mechanism of action of PD180970 involves inhibition of Bcr–Abl-mediated Stat5 signaling and provide further evidence that compounds in this structural class may represent potential therapeutic agents for CML.
Similar content being viewed by others
References
Afar D, Goga A, McLaughlin J, Witte O, Sawyers C . 1994 Science 264: 424–426
Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna J . 1996 Blood 87: 3837–3843
Besser D, Bromberg JF, Darnell JE, Hanafusa H . 1999 Mol. Cell. Biol. 19: 1401–1409
Bowman T, Broome M, Sinibaldi D, Wharton W, Pledger W, Sedivy J, Irby R, Yeatman T, Courtneidge S, Jove R . 2001 Proc. Natl. Acad. Sci. USA 98: 7319–7324
Bowman T, Garcia R, Turkson J, Jove R . 2000 Oncogene 19: 2474–2488
Bromberg J, Darnell JE . 2000 Oncogene 19: 2468–2473
Bromberg J, Horvath CM, Besser D, Lathem WW, Darnell JE . 1998 Mol. Cell. Biol. 18: 2553–2558
Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C, Darnell JE . 1999 Cell 98: 295–303
Carlesso N, Frank DA, Griffin JD . 1996 J. Exp. Med. 183: 811–820
Catlett-Falcone R, Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna J, Nunez G, Dalton W, Jove R . 1999 Immunity 10: 105–115
Chai SK, Nichols GL, Rothman P . 1997 J. Immunol. 159: 4720–4728
Chaturvedi P, Sharma S, Reddy EP . 1997 Mol. Cell. Biol. 17: 3295–3304
Coffer P, Koenderman L, de Groot R . 2000 Oncogene 19: 2511–2522
Cortez D, Stoica G, Pierce J, Pendergast A . 1996 Oncogene 13: 2589–2594
Danial NN, Pernis A, Rothman P . 1995 Science 269: 1875–1877
Danial NN, Rothman P . 2000 Oncogene 19: 2523–2531
Dang C, Resar L, Emison E, Kim S, Li Q, Prescott J, Wonsey D, Zeller KL . 1999 Exp. Cell Res. 253: 63–77
de Groot R, Raaijmakers J, Lammers J, Jove R, Koenderman L . 1999 Blood 94: 1108–1112
Dorsey J, Cunnick J, Lanehart R, Huang M, Kraker A, Bhalla K, Jove R, Wu J . 2002 Leukemia 16: 1589–1595
Dorsey J, Jove R, Kraker A, Wu J . 2000 Cancer Res. 60: 3127–3131
Druker B, Sawyers C, Kantarjian H, Resta D, Reese S, Ford J, Capdeville R, Talpaz M . 2001a N. Engl. J. Med. 344: 1038–1042
Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Lydon N, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers C . 2001b N. Engl. J. Med. 344: 1031–1037
Druker B, Tamura S, Buchdunger E, Ohno S, Segal G, Fanning S, Zimmermann J, Lydon N . 1996 Nat. Med. 2: 561–566
Epling-Burnette P, Liu J, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang J, Yang-Yen H, Karras J, Jove R, Loughran TJ . 2001a J. Clin. Invest. 107: 351–362
Epling-Burnette P, Zhong B, Bai F, Jiang K, Bailey R, Garcia R, Jove R, Djeu J, Loughran TJ, Wei S . 2001b J. Immunol. 166: 7486–7495
Fang G, Kim C, Perkins C, Ramadevi N, Winton E, Wittmann S, Bhalla K . 2000 Blood 96: 2246–2253
Frank DA, Varticovski L . 1996 Leukemia 10: 1724–1730
Gelfanov V, Burgess GS, Litz-Jackson S, King AJ, Marshall MS, Nakshatri H, Boswell HS . 2001 Blood 98: 2508–2517
Gesbert F, Griffin J . 2000 Blood 96: 2269–2276
Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P, Sawyer SC . 2001 Science 293: 876–880
Hazlehurst L, Damiano J, Buyuksal I, Pledger W, Dalton W . 2000 Oncogene 19: 4319–4327
Horita M, Andreu E, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna J . 2000 J. Exp. Med. 191: 977–984
Ibrado A, Huang Y, Fang G, Liu L, Bhalla K . 1996 Cancer Res. 56: 4743–4748
Ilaria RL, Van Etten RA . 1996 J. Biol. Chem. 271: 31704–31710
Jain S, Susa M, Keeler M, Carlesso N, Druker B, Varticovski L . 1996 Blood 88: 1542–1550
Jiang K, Zhong B, Gilvary D, Corliss B, Hong-Geller E, Wei S, Djeu J . 2000 Nature Immunol. 1: 419
Jonuleit T, Peschel C, Schwab R, van der Kuip H, Buchdunger E, Fischer T, Huber C, Aulitzky WE . 1998 Br. J. Haematol. 100: 295–303
Kolibaba K, Bhat A, Heaney C, Oda T, Druker B . 1999 Leuk. Lymphoma 33: 119–126
Kraker A, Hartl B, Amar A, Barvian M, Showalter H, Moore C . 2000 Biochem. Pharmacol. 60: 885–898
Landowski T, Shain K, Oshiro M, Buyuksal I, Painter J, Dalton W . 1999 Blood 94: 265–274
Lin T, Mahajan S, Frank D . 2000 Oncogene 19: 2496–2503
Lionberger J, Wilson M, Smithgall T . 2000 J. Biol. Chem. 275: 18581–18585
Lord J, McIntosh B, Greenberg P, Nelson B . 2000 J. Immunol. 164: 2533–2541
Lugo T, Pendergast A, Muller A, Witte O . 1990 Science 247: 1079–1082
Mes-Masson A, McLaughlin J, Daley G, Paskind M, Witte O . 1986 Proc. Natl. Acad. Sci. USA 83: 9768–9772
Nagar B, Bornmann W, Pellicena P, Schindler T, Veach D, Miller T, Clarkson B, Kuriyan J . 2002 Cancer Res. 62: 4236–4243
Nelson KL, Rogers JA, Bowman TL, Jove R, Smithgall TE . 1998 J. Biol. Chem. 273: 7072–7077
Nieborowska-Skorska M, Wasik M, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T . 1999 J. Exp. Med. 189: 1229–1242
Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K . 2002 Cancer Res. in press
Obaya A, Mateyak M, Sedivy J . 1999 Oncogene 18: 2934–2941
Onishi M, Nosaka T, Misawa K, Mui A, Gorman D, McMahon M, Miyajima A, Kitamura T . 1998 Mol. Cell. Biol. 18: 3871–3879
Pendergast A, Muller A, Havlik M, Maru Y, Witte O . 1991 Cell 66: 161–171
Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla K . 2001 Leukemia 15: 772–778
Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci P, Arlinghaus R, Pawson T . 1994 EMBO J. 13: 764–773
Reynolds J, Yang T, Qian L, Jenkinson J, Zhou P, Eastman A, Craig R . 1994 Cancer Res. 54: 6348–6352
Rhodes J, York R, Tara D, Tajinda K, Druker B . 2000 Exp. Hematol. 28: 305–310
Roumiantsev S, de Aos I, Varticovski L, Ilaria R, Van Etten R . 2001 Blood 97: 4–13
Rowley J . 1973 Nature 243: 290–293
Sawyers C, Callahan W, Witte O . 1992 Cell 70: 901–910
Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, Lee CK, Gerther R, Kitamura T, Frantsve J, Anastasiadou E, Loh ML, Levy DE, Ihle JN, Gilliland DG . 2000 Mol. Cell 6: 693–704
Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown M, Bunting K, Rothammer K, Roussel M, Ihle J . 2000 Blood 96: 2277–2283
Sillaber C, Gesbert F, Frank D, Sattler M, Griffin J . 2000 Blood 95: 2118–2125
Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger W, Jove R . 2000 Oncogene 19: 5419–5427
Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H, Wilson MB . 2000 Oncogene 19: 2612–2618
Socolovsky M, Fallon A, Wang S, Brugnara C, Lodish H . 1999 Cell 98: 181–191
Song J, Grandis J . 2000 Oncogene 19: 2489–2495
Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, Kataoka Y, Takai E, Mizuki M, Machii T, Wakao H, Kanakura Y . 2002 J. Biol. Chem. 277: 8076–8082
Thiesing J, Ohno-Jone SS, Kolibaba K, Druker B . 2000 Blood 96: 3195–3199
Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot R, Jove R . 1998 Mol. Cell. Biol. 18: 2545–2552
Wei S, Gilvary D, Corliss B, Sebti S, Sun J, Straus D, Leibson P, Trapani J, Hamilton A, Weber M, Djeu J . 2000 J. Immunol. 165: 3811
Wisniewski D, Lambek C, Liu C, Strife A, Veach D, Nagar B, Young M, Schindler T, Bornmann W, Bertino J, Kuriyan J, Clarkson B . 2002 Cancer Res. 62: 4244–4255
Yu C, Meyer D, Campbell G, Larner A, Carter-Su C, Schwartz J, Jove R . 1995 Science 269: 81–83
Zhou P, Qian L, Kozopas K, Craig R . 1997 Blood 89: 630–643
Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH . 1998 J. Biol. Chem. 273: 28065–28072
Acknowledgements
This work was supported by NCI grants CA55652 and CA82533 (to R Jove). We thank members of the laboratory for valuable discussions and the Moffitt Cancer Center Tumor Bank, Flow Cytometry and Molecular Imaging Core Facilities.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, M., Dorsey, J., Epling-Burnette, P. et al. Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21, 8804–8816 (2002). https://doi.org/10.1038/sj.onc.1206028
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206028
- Springer Nature Limited
Keywords
This article is cited by
-
Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer
Journal for ImmunoTherapy of Cancer (2017)
-
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL
Scientific Reports (2016)
-
A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells
Apoptosis (2016)
-
Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer
Archives of Pharmacal Research (2016)
-
Synthesis of 2-arylamino substituted 5,6-dihydropyrido[2,3-d]pyrimidine-7(8H)-ones from arylguanidines
Molecular Diversity (2012)